Tango Therapeutics, Inc. (TNGX) Reports In-Line Q1 EPS

Tango Therapeutics, Inc. (NASDAQ: TNGX) reported Q1 EPS of ($0.36), in-line with the analyst estimate of ($0.36). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $6.73 million.

For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.

You May Also Be Interested In

• Tennant Co. (TNC) Misses Q2 EPS by 53c; offers guidance
• Cooper-standard Holdings (CPS) Misses Q2 EPS by 72c ; Offers Guidance
• AMCON Distributing (DIT) Reports Q3 EPS of $2.85